Sclerostin-Binding Aptamers for Osteoporosis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoporosis, such as anti-resorptive agents and parathyroid hormone peptides, have limitations including adverse effects and high costs, necessitating the development of alternative anabolic drugs that can promote bone formation without immunogenicity, ease of production, low cost, and high stability.
Innovation Solution
Development of aptamers specifically targeting sclerostin, which are short single-stranded oligonucleotides with high affinity and specificity for sclerostin, offering advantages over monoclonal antibodies in terms of immunogenicity, production costs, and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are used to target sclerostin for bone anabolic therapy, then bone formation is promoted and bone mass increases, but high immunogenicity, high production cost, and instability requiring continuous cold chain occur
Solution Approach 1:
The patent uses aptamers as simplified copies or alternatives to monoclonal antibodies. Instead of using complex antibody molecules that trigger immune responses, the invention employs smaller oligonucleotide sequences that can be chemically synthesized to achieve similar therapeutic effects of blocking sclerostin while avoiding immunogenicity issues
Solution Approach 2:
The patent adopts aptamers that can be chemically synthesized at lower cost compared to expensive monoclonal antibody production. The aptamers are designed as disposable therapeutic agents that can be produced on-demand through chemical synthesis rather than complex biological manufacturing processes
2Reliability
If monoclonal antibodies are used to target sclerostin, then therapeutic efficacy is achieved, but production becomes expensive and laborious
Solution Approach 1:
The patent replaces the biological manufacturing system required for monoclonal antibodies with a chemical synthesis system for aptamers. Instead of using cell cultures and complex bioprocessing, the invention uses solid-phase chemical synthesis methods that are more controllable, scalable, and cost-effective
Solution Approach 2:
The patent changes the fundamental parameters of the therapeutic agent from protein-based (antibodies) to nucleic acid-based (aptamers). This parameter change enables transition from biological manufacturing to chemical synthesis, dramatically simplifying production and reducing costs while maintaining therapeutic efficacy
3Reliability
If monoclonal antibodies are used to target sclerostin, then bone formation is promoted, but stability decreases requiring continuous cold chain for transportation and storage
Solution Approach 1:
The patent creates a more stable version of the therapeutic agent by copying the essential function of antibodies (blocking sclerostin) using aptamers with inherent chemical stability. The oligonucleotide structure of aptamers provides resistance to degradation and maintains stability at higher temperatures, eliminating cold chain requirements
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The aptamers effectively inhibit the biological activity of sclerostin, promoting bone formation and increasing bone mass with improved stability and reduced production costs, thus providing a viable alternative for treating osteoporosis.
Implementation Method 1
Aptamers are short single-stranded oligonucleotides which bind to their targets through conformational complementarity
Data Source
AI summary
The invention relates to the field of biomedicine. Specifically, the present invention relates to aptamers against sclerostin and uses thereof, especially uses in the treatment of sclerostin-related diseases such as osteoporosis.